GSK Takes An Option On Concert’s Preclinical Compounds
This article was originally published in The Pink Sheet Daily
Executive Summary
In the latest in a long string of alliances sporting options, the Big Pharma lends its imprimatur to Concert’s platform for creating deuterated versions of existing molecules.